Lipocine Inc. reported that it presented two posters on its drug LPCN 2101 at the American Epilepsy Society Annual Meeting from December 5 to 9, 2025. The posters cover clinical pharmacokinetics and tolerability, as well as oral toxicokinetics related to treating epilepsy.